Clinical Trials Logo

Clinical Trial Summary

In this study, the task was to evaluate the effectiveness of prescribing small doses of quetiapine (25-75 mg) for bipolar patients in remission in order to relieve symptoms of impulsivity.


Clinical Trial Description

The purpose of this study is to study the efficacy and safety of the administration of Quetiapine ® in small doses (25-75 mg / day) to patients diagnosed with bipolar disorder who are in an euthymic state with signs of impaired impulse control. The method of administration, dosage regimen and duration of taking quetiapine in this study: 1-3 tablets from one to 3 times a day, regardless of food intake for 28 days. Each patient included in the program will be given a package with the drug for 14 days of admission. In the first 14 days of administration, dose adjustment is possible in the range from 25 to 75 mg, depending on individual tolerability. The decision on correction is made by the doctor based on a phone call to the patient after the first week of taking the drug at a dose of 25 mg. Correction is also possible at a later or earlier date during the first two weeks of therapy. At visit 2, the patient will have to provide the doctor with a package of the drug as part of the compliance assessment. At visit 2, the doctor should give the patient packages with the drug for 28 days of admission and ask them to bring packages to assess compliance and account for the drug for visit 3. Screening (Visit 1 / Day 0) The inclusion of the subject in the program will be carried out on the basis of an assessment of demographic, clinical characteristics, anamnesis data. Prior to the start of the examination, the subject must be provided with oral information about the nature of the study, an informed consent form for signing. The following procedures will be performed during the screening: - Collection of demographic data; - Medical history (previous and concomitant diseases, surgical interventions, allergic history, gynecological history); - Confirmation of the diagnosis - Evaluation of inclusion/non-inclusion criteria; -- Registration of the drug (or other) therapy that the study participant receives; - The presence of bad habits; - Rating on the YMRS scale; - Assessment on the MADRS scale; - Assessment on the Barratt impulsivity scale; - Score on the Go-no-go task - Score on the Ballon Analog Risk Task (BART) - Delivery of the drug - Functional magnetic resonance imaging (fMRI) (optional) Visit 2 / Day 14±3 The following procedures will be carried out on Visit 2: - Registration of the drug (or other) therapy that the study participant receives; - Assessment of the subject's compliance; - Correction of the dose of the drug*; - Registration of adverse reactions / adverse events; - Assessment on the Barratt impulsivity scale; - Score on the Go-no-go task - Score on the Ballon Analog Risk Task (BART) - Delivery of the drug - fMRI (optional) Visit 3 / Day 42±3 Registration of the drug (or other) therapy that the study participant receives; - Assessment of the subject's compliance; - Registration of adverse reactions / adverse events; - Assessment on the Barratt impulsivity scale; - Score on the Go-no-go task - Score on the Ballon Analog Risk Task (BART) - fMRI (optional) Concomitant therapy Within the framework of this study, patients can receive any pharmacotherapy therapy, with the exception of quetiapine in higher doses than prescribed by the protocol. At each visit, the doctor should interview the patient about any medications used by the patient during participation in the study. Information about the patient's intake of concomitant medications is entered by the doctor in the IRC. Functional magnetic resonance imaging (fMRI) As part of this study, an additional fMRI procedure will be performed for a part of patients (10 people) to assess the functional activity of the brain when performing the Go-no-GO test. Total duration of the study The expected duration of the subjects' participation in the study corresponds to the expected duration of taking the drug and for each participant will be 42 ± 3 days. The inclusion of patients in the study will continue until their total number reaches 30 people. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05098353
Study type Interventional
Source Federal Stare Budgetary Scientific Institution, Mental Health Research Center
Contact Margarita A Morozova, PhD
Phone +74951090393
Email margmorozova@gmail.com
Status Recruiting
Phase N/A
Start date April 10, 2021
Completion date December 1, 2021

See also
  Status Clinical Trial Phase
Completed NCT03275714 - Evaluation of an App for Smartphones for People With a Bipolar Affective Disorder N/A
Completed NCT03249857 - Study of Sensorimotor Compatibility Effects in Bipolar Affective Disorder. N/A
Completed NCT01722344 - Improving Work Outcome for People With Severe Mental Illness N/A
Completed NCT01431092 - Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia Phase 4
Completed NCT01315028 - Bipolar Intervention Study: Cognitive Interpersonal Therapy N/A
Terminated NCT00805493 - Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder Phase 2
Completed NCT00436020 - rTMS in the Treatment of Bipolar Depression N/A
Withdrawn NCT00397605 - Cannabinoids in Bipolar Affective Disorder N/A
Recruiting NCT05860101 - Compassion-Focused Therapy for Distressing Mood Swings: A Case Series N/A
Recruiting NCT06176456 - Personalized Prospective Study Evaluation of the Efficacy and Safety of Noninvasive Neuromodulation of TMS in Subjects With Catatonia N/A
Terminated NCT03310593 - Cannabidiol as an Adjunctive Treatment for Bipolar Depression Phase 2/Phase 3
Recruiting NCT05406414 - The Efficacy of a Transdiagnostic Sleep and Circadian Intervention for Patients With Mental Disorders and Sleep Problems N/A
Completed NCT02773108 - Somatic Comorbidities in Psychiatric Patients
Recruiting NCT00474357 - Myths About Bipolar Affective Disorder: The Role of Structured Group Psychoeducation Therapy N/A
Withdrawn NCT00327756 - Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder Phase 2
Completed NCT02453217 - The Potential Efficacy of the Chinese Health Improvement Profile- A Pilot Clustered Randomised Controlled Trial N/A
Completed NCT05683431 - Using Neuroplasticity-Based Computerized Training to Improve Emotion Regulation in Bipolar Disorder (BRAINS) N/A
Not yet recruiting NCT05915312 - Exosome for Early Diagnosis of Bipolar Affective Disorder
Completed NCT00186758 - Transcranial Magnetic Stimulation in Bipolar Depression Phase 4
Completed NCT02083978 - Bipolar Research Study Using MR Imaging N/A